(BCYC) – Globe Newswire
-
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
-
Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director
-
NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair
-
Evelo Biosciences Announces Appointments of Jose-Carlos Gutiérrez-Ramos and Tonya Williams to Board of Directors
-
Annual Changes to the Nasdaq Biotechnology Index
-
OMass Unveils Rich Drug Discovery Pipeline Targeting Intractable or Inadequately Drugged Membrane and Complex-bound Proteins
-
ORION BIOTECHNOLOGY WELCOMES NEW MEMBERS OF SCIENTIFIC ADVISORY BOARD
-
OXURION NV to Present at Wet AMD and DME Drug Development Summit
-
OXURION NV to Present at Wet AMD and DME Drug Development Summit
-
Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD
-
Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD
-
Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group
-
Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group
-
OXURION to Participate in Upcoming Investor Meetings
-
OXURION to Participate in Upcoming Investor Meetings
-
Sitryx appoints Pierre Legault as Chairman of its Board of Directors
-
Oxurion NV Business and Financial Update – FY 2020
-
Oxurion NV Business and Financial Update – FY 2020
-
OXURION to Participate in Upcoming Investor Meetings
-
OXURION to Participate in Upcoming Investor Meetings
-
Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer
-
Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer
-
OXURION to Participate in Upcoming Investor Meetings
-
TRHC’s DoseMeRx® Partners with Physiomics to Provide Precision Dosing for Oncology Medications
-
OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices
-
OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices
-
Oxurion NV Business Update – Q3 2020
-
Oxurion NV Business Update – Q3 2020
-
Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer
-
Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer
-
Invitation OXURION R&D Investor Day – Virtual - 15 October 2020 at 5.30pm CET/ 11.30am ET
-
Save The Date: Oxurion to host Virtual R&D Investor Day on 15 October 2020
-
Oxurion NV to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtual Meeting, Oct 2-4
-
Oxurion NV Business Update - H1 2020
-
Oxurion NV Business Update - H1 2020
-
Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference
-
Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September
-
Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September
-
Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)
-
Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)
-
Oxurion NV appoints Grace Chang, M.D., Ph.D. as Chief Medical Officer
-
Oxurion NV appoints Grace Chang, M.D., Ph.D. as Chief Medical Officer
-
Annual results for the year ended 31 March 2020
-
Amolyt Pharma Appoints Pierre Legault as a Director and Chairman of its Board of Directors as Company Transitions into Clinical Stage
-
Oxurion NV Business Update - Q1 2020
-
Oxurion NV Business Update - Q1 2020
-
Celyad Appoints Seasoned Industry Executives to Board of Directors
-
Oxurion NV Business Update – FY 2019
-
Oxurion NV Business Update – FY 2019
Back to BCYC Stock Lookup
